Instem has delivered a strong set of FY15 prelims, in line to slightly ahead of expectations. Strong organic revenue growth of 22% translated into a 49% increase in operating profits, driven by increased activity across the group. The outlook remains very positive, particularly around the FDA’s SEND initiative, but also supported by buoyant conditions generally in the early drug development market. Recent contract wins leave our forecasts looking increasingly well underpinned, with further potential upside to come from acquisitions.